Table 2 Relationship between S6 phosphorylation or GLUT1 and patient characteristics

pS6 < 4 (n = 22)

pS6 ≥ 4 (n = 17)

P value

Age (y)

74.1 ± 7.4

73.5 ± 5.2

0.792

Sex (male/female)

18/4

13/4

0.683

Body mass index (kg/m²)

22.3 ± 3.1

22.2 ± 3.9

0.882

CEA (ng/mL)

3.3 ± 1.9

4.7 ± 3.7

0.144

CA19-9 (U/mL)

23.4 ± 21.7

1481.5 ± 3335.3

0.047*

SUV max of FDG-PET

4.8 ± 0.7

11.2 ± 6.4

0.002*

Tumor size (mm)

34.1 ± 17.0

38.1 ± 15.8

0.456

Tumor type (Papillary/Nodular/Flat)

2/13/7

0/12/5

0.080

T Stage (≤ 2/3 ≤)

16/6

4/13

0.002*

Nodal status (N0/N1/N2)

16/4/2

9/7/1

0.285

Lymphatic invasion (-/ +)

13/9

5/12

0.063

Vascular invasion (-/ +)

13/9

5/12

0.063

Nerve invasion (-/ +)

6/16

3/14

0.475

UICC Stage (≤ IIA/IIB ≤)

13/9

2/15

0.003*

GLUT-1 < 4 (n = 22)

GLUT-1 ≥ 4 (n = 17)

P value

Age (y)

73.9 ± 7.3

73.7 ± 5.3

0.946

Sex (male/female)

18/4

13/4

0.683

Body mass index (kg/m²)

22.1 ± 3.1

22.4 ± 3.8

0.748

CEA (ng/mL)

3.3 ± 1.9

4.7 ± 3.7

0.118

CA19-9 (U/mL)

24.3 ± 21.8

1480.4 ± 3335.8

0.047*

SUV max of FDG-PET

4.8 ± 1.3

10.6 ± 1.4

0.007*

Tumor size (mm)

35.5 ± 19.3

36.2 ± 4.0

0.899

Tumor type (Papillary/Nodular/Flat)

2/12/8

0/13/4

0.379

T Stage (≤ 2/3 ≤)

15/7

5/12

0.025*

Nodal status (N0/N1/N2)

18/2/2

7/9/1

0.009*

Lymphatic invasion (-/ +)

14/8

4/13

0.023*

Vascular invasion (-/ +)

13/9

5/12

0.063

Nerve invasion (-/ +)

7/15

2/15

0.251

UICC Stage (≤ IIA/IIB ≤)

13/9

2/15

0.003*